The test produces a line on the paper that appears depending on whether haemoglobin is present in a sample placed on it.
The researchers say that the printed paper test could also be adapted to different purposes by exchanging the antibody printed on the paper for another.
The technology could be applied to produce a rapid diagnostics tests in the healthcare market, or to bring additional features to packaging or labelling. The technology also presents new possibilities for ensuring product authenticity.
The bioactive paper research has been funded by Tekes, the Finnish Funding Agency for Technology and Innovation, with support from commercial partners UPM-Kymmene Corporation, Tervakoski, BASF, Orion Diagnostica, Hansaprint, Oy Medix Biochemica, Starcke Securities and Eagle Filter.
Poll: Should the UK’s railways be renationalised?
I think that a network inclusive of the vehicles on it would make sense. However it remains to be seen if there is any plan for it to be for the...